P328

Coordinator: Julie M. Zaetta, MD

Eric A. Hueul, MD Riad Salem, MD; MBA Jeff H. Geschwind, MD Timothy W.l. Clark, MD

Daniel B. Brown, MD Julie M. Zaetta, MD Michael C. Soulen, MD

RENOVASCULAR DISEASE: THE ROLE OF IR IN DIAGNOSIS, TREATMENT AND MANAGEIVIENT (WK31) Objectives: Upon completion of this workshop, the attendee should be able to:

1. Discuss the role of noninvasive and angio­graphic evaluation in renal vascular disease.

2. Discuss strategies for treating renal artery steno­sis.

3. Review and discuss percutaneous therapy. 4. Discuss the role of adjunct medications for renal

angioplasty stenting. 5. Discuss outcomes of percutaneous intervention. 6. Discuss complications and their treatment.

Coordinator: David J. Spinosa, MD

John H. Rundback, MD Patrick C. MaUoy, MD Alan H. Matsumoto, MD Mohsin Saeed, MD Louis G. Martin, MD Souheil Saddekni, MD Michael A. Bettma[UJ, MD Timothy P. Murphy, MD David W. Trost, MD Thomas A. Sos, MD Vincent Oliva, MD David Spinosa, MD

PERIPHERAL ENDOGRAFTS AND VASCULAR ACCESS (WK32) Objectives: Upon completion of this workshop, the attendee should be able to:

1. Define the indications and contra indications for peripheral (non-aortic) stent-graft implantation.

2. Discuss the available endografts: features, strengths, and limitations.

3. Explain the role of stent-grafts for the patient with non-aortic aneurysms, trauma, dialysis-re­lated stenoses, or recurrent TIPS failures.

4. Describe the technique of femoral artery or ret­roperitoneal ilia&..artery exposure, and manage­ment issues related to introduction of large cath­eters into the arterial system.

5. Learn how to make a simple stent-graft for emergency use when an FDA-approved device is not available. ~

::.::.~ "'-

Coordinator: Charles P. Semba~ MD

Daniel Sze, MD, PhD Mahmood K. Razavi, MD

Stephen T. Kee, MD

ENDOLUMINAL TREATMENT FOR ABDOMINAL AORTIC ANEURYSMS (AAA) (WK33) Objectives: Upon completion of this workshop, the attendee should be able to:

1. Perform and interpret the screening tests for AM stent graft repair.

2. Measure, order, and strategize device selection and approach for AAA stent graft repair.

3. Identify and compare different models and de­signs of AM stent grafts.

4. Recognize the secondary interventions involved in AAA stent graft repair (including endoleak evaluation and therapy).

Coordinator: Stuart C. GeUer, MD

THROMBOLYTIC THERAPY FOR ARTERIAL DISEASE (WK34) Objectives: Upon completion of this workshop, the attendee should be able to:

1. Properly select candidates for arterial thrombol­ysis and be able to identify patients at increased risk for complications.

2. Discuss the technical aspects of arterial throm­bolysis, including: choice of thrombolytic agent, dosing regimens and delivery systems.

3. Implement safe and effective protocols for cur­rently available thrombolytic agents.

4. Discuss the safe and effective use of anticoagu­lation and oral platelet inhibitors during and after thrombolytic thera py.

5. Identify the currently available IIb IIIa platelet inhibitors and understand their mechanism of action.

6. Discuss the current and potential complemen­tary roles for the IIb IIIa platelet inhibitors dur­ing arterial thrombolysis .

7. Discuss the role of mechanical devices during arterial thrombolysis .

8. Explain how to handle complex or difficult sit­uations that may arise during thrombolysis pro­cedures.

9. Explain patient care issues during and immedi­ately after thrombolytic therapy.

Coordinator: John E. Aruny, MD

David L. Waldman, MD James L. Swischuk, MD John E. Aruny, MD Pamela Flick, lvlD

Hal L. Folander, MD Tunothy P. Murphy, MD Dominic Carl Yee, MD Richard Shlansky-Goldberg,

MD

THROMBOLYTIC THERAPY FOR VENOUS DISEASE (WK35) Objectives: Upon completion of this workshop, the attendee should be able to:

1. Explain the role of thrombolysis in patients with iliofemoral deep venous thrombosis and upper extremity venous occlusions, . using the cur­rently available pharmacologic agents .

2. List the technical aspects of venous thromboly­sis, including delivery systems, dosing regimens and safe and effective management protocols.

3. Discuss the potential role of adjunctive therapy.